Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.

Authors:
Gissel C; Götz G; Repp H.

Journal:
Z Rheumatol

Publication Year: 2016

DOI:
10.1007/s00393-016-0071-9

PMCID:
PMC5127857

PMID:
27080399

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Z Rheumatol

Abbreviation: Z Rheumatol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
High- and low-dose cyclophosphamide in Egyptian lupus nephritis patients: a multicenter retrospecti…
Elaziz MMA; Gamal SM; Fayed A and 3 more (2023) - Transparency Score: 3/6
Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany…
Fiehn C; Zinke S; Haas JS and 4 more (2023) - Transparency Score: 3/6
Survey on the working, training, and research conditions of resident physicians in internistic and …
Proft F; Vossen D; Baraliakos X and 14 more (2023) - Transparency Score: 3/6
COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement.
Kim Y; Kang J; Lee SG and 1 more (2022) - Transparency Score: 2/6
Digitalization and disruptive change in rheumatology.
Richter P; Richter JG; Lieb E and 4 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest C. Gissel, G. Götz and H. Repp state that there are no conflicts of interest. The accompanying manuscript does not include studies on humans or animals."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025